Clinical Trial Update: A Phase IIa Study of NT-KO-003 for Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase IIa study evaluating NT-KO-003 for relapsing-remitting multiple sclerosis has completed, according to trial records.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• NT-KO-003 (NT-KO-003)

Snippet

Sponsor: Neurotec Pharma | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED